Speech by Robert M. Califf, M.D., MACC (Remarks as prepared for delivery) Good morning. It’s my great pleasure to be with you today. The last time I had the
Experts discuss how the results were conveyed and what they mean for embolic protection during TAVI moving forward.
Arrivo BioVentures announces SP-624 demonstrated robust efficacy in females with major depressive disorder in Phase 2 study of novel mechanism
Offers solution to accelerate identity intelligence through simplified, yet extensive, visibility of user activity.
The writing was on the wall. The FDA spelled out its qualms with Minerva Neurosciences’ schizophrenia drug candidate roluperidone in 2020. Nevertheless, the biotech pushed forward and had meetings with the regulator to attempt to assuage concerns and get its drug to market. So the biotech went ahead…
Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA submission for PNT2001 program in H1 2023 INDIANAPOLIS, Oct. 17, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Glo…
/PRNewswire/ -- Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and...
According to the company, latanoprost ophthalmic solution 0.005% successfully met the primary and all secondary endpoints, and it plans to file an NDA with the FDA in Q1 2023.
As society becomes more open to and reliant on these tools, it is the responsibility of technology companies, especially those tasked with assisting people’s mental health, to build and maintain artificial intelligence and machine learning models that adapt alongside societal needs.
New York, New York--(Newsfile Corp. - October 16, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen" or the "Company") and certain of its
INOVIO recently announced positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for treating HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults. RRP is a rare disease primarily caused by HPV types 6 and/or 11. RRP is characterized by the…
Briefing data show Makena was ineffective in reducing preterm birth, improving neonatal outcomes
A study from the Republic of Korea confirmed the safety and efficacy of Herzuma (CT-P16) in patients with heavily pretreated human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
The investigational respiratory syncytial virus vaccine had an overall efficacy of 82.6% against RSV-LRTD, 94.6% against severe disease, and 94.1% in adults with comorbidities.
A prospective translational study, identified a differential expression of genes encoded for costimulatory molecules and cytokines between patients with eSCLC who responded with longer progression-free survival so the new first-line standard of care PEA and those who had shorter PFSs.
GuruFocus Article or News written by Value_Insider and the topic is about:
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo® (cemiplimab) as a monotherapy for the treatment of adult patients with recurrent or metastatic cervic…
A post-AAO 2022 discussion on avacincaptad pegol in GA and what this groundbreaking treatment represents in filling a currently unmet need.
Scientific Reports - Efficacy of Moraceae with chlorhexidine mouthwash on the microbial flora of critically ill intubated patients: a randomized controlled pilot study